From Men's Health · Korin Miller · · 1m 10s
FDA Warns GLP-1 Users About Vision Risk
FDA flags rare vision loss risk for GLP-1 medication users.
In brief
FDA flags rare vision loss risk for GLP-1 medication users. FDA warns GLP-1 drugs may cause permanent vision loss in rare cases but stress risk remains extremely low. Originally reported by Men's Health.
Quick answers
- What is NAION?
- NAION is a rare condition that can cause permanent vision loss in one eye, with symptoms including acute painless decreased vision.
- What is the key takeaway from FDA Warns GLP-1 Users About Vision Risk?
- FDA warns GLP-1 drugs may cause permanent vision loss in rare cases but stress risk remains extremely low.
FDA Drug Warning
The FDA released a drug safety communication warning about potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) for GLP-1 medication users.
“Patients and caregivers should be aware of a potential increased risk of NAION, a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss, with GLP-1 RA use”
What is NAION?
NAION is a rare condition that can cause permanent vision loss in one eye, with symptoms including acute painless decreased vision.
FDA's Warning Details

The FDA requires all GLP-1 medication manufacturers to add NAION risk information to their product labels.
Expert Opinions
Doctors stress the risk remains extremely rare despite potential for permanent vision loss in affected cases.
Why FDA Warned
The FDA cites a 2024 study in JAMA Ophthalmology and its own meta-analyses showing NAION cases reported for all GLP-1 RA products.
Risk Statistics
FDA meta-analysis shows 6.4 NAION events per 100,000 GLP-1 users per year.
Expert Reactions
Doctors say the risk is extremely rare but patients should stay informed without panicking.
The short version
FDA warns GLP-1 drugs may cause permanent vision loss in rare cases but stress risk remains extremely low.
Read the TL;DR — this story on one card.





